Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
AlphaMedix (ORM-2110)
i
Other names:
ORM-2110, 212 lead-labeled peptide, 212Pb AR RMX, 212-Pb-Targeted-Alpha-Emmitter-Therapy, 212Pb-AR-RMX, 212Pb-alphamedix, 212Pb-somatostatin analogue, Lead-212 radiotherapy, ORM 2110, ORM2110, 212Pb-labeled peptide, Pb212-octreotide analog, ²¹²Pb-DOTAMTATE, Pb-212 radiotherapy
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Orano, RadioMedix, Sanofi
Drug class:
Alpha radiation emitter, SSTR2 inhibitor
Related drugs:
‹
Ac-225 ErbB3 targeted radiotherapy (4)
lintuzumab-Ac225 (4)
RYZ101 (2)
radium Ra-223 dichloride (2)
BAY2701439 (1)
I-131-apamistamab (1)
Undisclosed EGFRvIII-targeted alpha therapy (1)
211At-OKT10-B10 (0)
212Pb-DOTAM-GRPR1 (0)
AAA817 (0)
AB001 (0)
CONV01-α (0)
FPI-1434 (0)
FPI-1966 (0)
FPI-2265 (0)
Iomab-ACT (0)
JNJ-6420 (0)
VMT-01 (0)
VMT-𝛼-NET (0)
[²¹¹At]PTT (0)
BAY 2315497 (0)
BAY 2287411 (0)
PEN-221 (1)
177Lu-LNC1010 (0)
EBTATE (0)
lutetium-177 DOTA satoreotide (0)
67Cu MeCOSar octreotate (0)
177Lu-edotreotide (0)
Re (0)
XmAb18087 (0)
Ac-225 ErbB3 targeted radiotherapy (4)
lintuzumab-Ac225 (4)
RYZ101 (2)
radium Ra-223 dichloride (2)
BAY2701439 (1)
I-131-apamistamab (1)
Undisclosed EGFRvIII-targeted alpha therapy (1)
211At-OKT10-B10 (0)
212Pb-DOTAM-GRPR1 (0)
AAA817 (0)
AB001 (0)
CONV01-α (0)
FPI-1434 (0)
FPI-1966 (0)
FPI-2265 (0)
Iomab-ACT (0)
JNJ-6420 (0)
VMT-01 (0)
VMT-𝛼-NET (0)
[²¹¹At]PTT (0)
BAY 2315497 (0)
BAY 2287411 (0)
PEN-221 (1)
177Lu-LNC1010 (0)
EBTATE (0)
lutetium-177 DOTA satoreotide (0)
67Cu MeCOSar octreotate (0)
177Lu-edotreotide (0)
Re (0)
XmAb18087 (0)
›
Associations
(1)
News
Trials
Filter by
Latest
6ms
ALPHAMEDIX02: Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients (clinicaltrials.gov)
P2, N=69, Active, not recruiting, Radiomedix, Inc. | Recruiting --> Active, not recruiting
6 months ago
Enrollment closed
|
SSTR (Somatostatin Receptor)
|
AlphaMedix (ORM-2110)
1year
ALPHAMEDIX02: Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients (clinicaltrials.gov)
P2, N=68, Recruiting, Radiomedix, Inc. | N=34 --> 68 | Trial completion date: Dec 2023 --> Oct 2026 | Trial primary completion date: Dec 2022 --> Oct 2026
1 year ago
Enrollment change • Trial completion date • Trial primary completion date
|
SSTR (Somatostatin Receptor)
|
AlphaMedix (ORM-2110)
almost3years
ALPHAMEDIX02: Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients (clinicaltrials.gov)
P2, N=34, Recruiting, Radiomedix, Inc. | Not yet recruiting --> Recruiting
almost 3 years ago
Clinical • Enrollment open
|
SSTR (Somatostatin Receptor)
|
AlphaMedix (ORM-2110)
almost3years
ALPHAMEDIX02: Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients (clinicaltrials.gov)
P2, N=34, Not yet recruiting, Radiomedix, Inc.
almost 3 years ago
Clinical • New P2 trial
|
SSTR (Somatostatin Receptor)
|
AlphaMedix (ORM-2110)
over3years
ALPHAMEDIX01: Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET (clinicaltrials.gov)
P1, N=33, Recruiting, Radiomedix, Inc. | Completed --> Recruiting | Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2021 --> Jul 2022
over 3 years ago
Clinical • Enrollment open • Trial completion date • Trial primary completion date
|
SSTR (Somatostatin Receptor)
|
AlphaMedix (ORM-2110)
over3years
ALPHAMEDIX01: Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET (clinicaltrials.gov)
P1, N=33, Completed, Radiomedix, Inc. | Recruiting --> Completed | N=50 --> 33 | Trial completion date: Nov 2021 --> Jul 2021
over 3 years ago
Clinical • Trial completion • Enrollment change • Trial completion date
|
SSTR (Somatostatin Receptor)
|
AlphaMedix (ORM-2110)
over3years
ALPHAMEDIX01: Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET (clinicaltrials.gov)
P1, N=50, Recruiting, Radiomedix, Inc. | Trial primary completion date: Jul 2020 --> Jun 2021
over 3 years ago
Clinical • Trial primary completion date
|
SSTR (Somatostatin Receptor)
|
AlphaMedix (ORM-2110)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login